Cannabix Technologies and Omega Laboratories Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection

Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) and Omega Laboratories, ...

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environmentThe FDA requires that ...
STAT

Trump’s win puts future oversight of lab-made tests in jeopardy

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.
JD Supra

FDA Seeks to Increase Regulatory Oversight of Laboratory Developed Tests

On October 3, the US Food and Drug Administration (FDA) issued a proposed rule regarding the regulation of in vitro diagnostic products (IVDs). In this proposed rule, the FDA announced its intent to ...
GlobalData on MSN

SkylineDX’s predictive melanoma test secures FDA breakthrough designation

SkylineDX’s test stratifies cutaneous melanoma patients into metastatic risk categories to inform treatment decisions.

Omega Laboratories and Cannabix Technologies Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection

Omega Laboratories, Inc. ("Omega"), and Cannabix Technologies Inc. ("Cannabix") (CSE: BLO) (OTCID: BLOZF) announce the development and validation of ...